Hologic, Inc. (HOLX)
Fair bewertetFundamental
~0
Kurs
$-
Marktkapitalisierung
-
Teil 1 · Was das Unternehmen wert ist
Übersicht
Hologic makes medical devices and diagnostic tests focused on women's health. It builds the mammography and biopsy systems many hospitals use for breast-cancer screening, the molecular and cytology lab equipment that runs tests for infections and cervical cancer, surgical devices used in gynecological procedures such as fibroid removal, and bone-density scanners. Most of its products are sold to hospitals, imaging centers and diagnostic labs, either directly or through distributors and group purchasing contracts.
Wie das Geld verdient wird
Revenue mixes one-time capital equipment sales, such as a mammography or bone-density system, with recurring, higher-margin consumables that the equipment's installed base keeps buying: diagnostic assay cartridges, biopsy needles and single-use surgical instruments. In the US, large hospital groups buy through group purchasing organizations that negotiate on behalf of most hospitals, which caps how much pricing power any single product can hold even where the equipment locks a customer in.
Umsatz nach Segment
Molecular and cytology tests run on Hologic's lab instruments, covering infectious disease and cervical-cancer screening.
Mammography and breast-biopsy systems, the segment's largest source of capital-equipment revenue.
Devices for gynecological surgical procedures plus bone-density scanners, the two smallest of Hologic's business lines.
Wettbewerbsvorteil
Wechselkosten · SchmalA hospital that installs Hologic's Panther molecular-testing platform or its mammography systems keeps buying Hologic's matched consumables and service contracts for the equipment's life, since switching means requalifying a new system with clinicians and regulators. The advantage is narrow because Roche, BD and Siemens Healthineers sell comparable platforms and actively compete for the same equipment placements.
Was die Nachfrage antreibt
DefensivCancer screening, infectious-disease testing and gynecological procedures follow clinical guidelines and reimbursement coverage rather than discretionary spending, which makes underlying demand fairly steady. The more cyclical piece is capital equipment: hospitals can defer replacing a mammography system in a tight budget year even while the tests it enables keep being ordered.
Wichtigste Risiken
- Reimbursement and healthcare policy risk — Sales depend on government healthcare programs and private insurers continuing to cover and reimburse Hologic's tests and procedures at workable rates; adverse coverage or guideline changes reduce market acceptance.
- Group purchasing organization pricing pressure — Group purchasing organizations negotiate on behalf of most US hospitals and can push for steep discounts, limiting how much Hologic can charge even for products with a loyal installed base.
- Concentration in two business lines — Diagnostics and Breast Health together make up roughly four-fifths of revenue, so a setback in either, such as falling COVID-era test demand, affects the company disproportionately.
- Competition from larger, diversified rivals — Hologic competes against larger, more diversified medical-technology and diagnostics companies that can outspend it on research and undercut on price in individual product categories.
Die Argumente dafür
Buyers argue that women's-health screening and testing volumes are structurally growing as guidelines expand, that the installed base of mammography and molecular-diagnostics equipment keeps generating high-margin consumable sales for years, and that fiscal 2025 growth in Breast Health and GYN Surgical shows the non-COVID business is healthy on its own.
Die Argumente dagegen
Sellers worry that group purchasing organizations will keep compressing per-unit pricing, that Diagnostics revenue has yet to fully offset the loss of pandemic-era test volumes, and that a portfolio this concentrated in two business lines is vulnerable to a single reimbursement or competitive setback in either one.
Written by the editors, published on 18. August 2026
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
Hologic's 10-K names GE HealthCare as a primary Breast Health rival: both sell 3D mammography and tomosynthesis systems to the same hospitals and imaging centres, and compete for the same installed base and service contracts.
BD is the competitor Hologic names first in cervical cancer screening: its liquid-based cytology and HPV assays go after the same clinical laboratories that buy ThinPrep and the Panther molecular platform.
Named alongside GE as Hologic's main Breast Health competitor, Siemens Healthineers sells mammography and breast biopsy systems to the same radiology departments, and also competes in laboratory diagnostics.
Through Roche Diagnostics, named in Hologic's 10-K, it sells HPV and molecular infectious-disease assays on high-throughput analysers that compete directly with Hologic's Panther system for laboratory testing volumes.
Cited in the 10-K as a full-suite surgical rival, Medtronic sells gynaecological surgery devices to the same hospitals and surgeons that Hologic targets with NovaSure and MyoSure.
Begrenzte Finanzdaten verfügbar (0 % der Kennzahlen). Scores spiegeln möglicherweise die Fundamentaldaten dieses Unternehmens nicht genau wider.
Bilanz & Liquidität
Umsatz
-
Nettogewinn
-
Freier Cashflow
-
Gesamtes Eigenkapital
-
Gesamtverbindlichkeiten
-
Current Ratio
3.75
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Keine EPS-Daten verfügbar
Umsatz & Nettogewinn
Keine Ertragsdaten verfügbar
Freier Cashflow
Keine Cashflow-Daten verfügbar
Ertragsaufschlüsselung
Keine Ertragsdaten verfügbar
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$31.68
Aktueller Kurs
-
Sicherheitsmarge
-
Innerer-Wert-Spanne
$30.09 - $33.26
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
31.20
ROE
11.0%
P/B-Verhältnis
-
P/FCF
-
Bruttomarge
-
ROIC
-
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Fundamentalanalyse-Kriterien
Bestanden (0)
Nicht bestanden (0)
Nicht verfügbar (1)
- Error fetching data
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Unternehmensführung
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for HOLX, sourced from Markets Gazette.
- 4/8/2026POSITIVEHologic Goes Private In $18 Billion Blackstone, TPG Acquisition
Blackstone and TPG have successfully completed their acquisition of Hologic Inc., taking the medical technology company private in a deal valued at up to $18 billion, or $79 per share. This transaction marks a significant shift for Hologic, moving it from public trading to private ownership under the stewardship of its new private equity owners. Investors who held Hologic stock prior to the acquisition will receive the specified cash consideration, realizing a return on their investment.
via Markets Gazette